KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Accumulated Expenses (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Accumulated Expenses for 16 consecutive years, with $1.8 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Accumulated Expenses rose 24.86% year-over-year to $1.8 billion, compared with a TTM value of $1.8 billion through Sep 2024, up 24.86%, and an annual FY2023 reading of $1.6 billion, down 23.82% over the prior year.
  • Accumulated Expenses was $1.8 billion for Q3 2024 at Thermo Fisher Scientific, up from $1.5 billion in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $2.4 billion in Q4 2021 and bottomed at $755.0 million in Q1 2020.
  • Average Accumulated Expenses over 5 years is $1.6 billion, with a median of $1.5 billion recorded in 2020.
  • The sharpest move saw Accumulated Expenses skyrocketed 89.7% in 2020, then decreased 23.93% in 2023.
  • Year by year, Accumulated Expenses stood at $1.9 billion in 2020, then rose by 26.67% to $2.4 billion in 2021, then decreased by 13.68% to $2.1 billion in 2022, then fell by 23.82% to $1.6 billion in 2023, then increased by 14.22% to $1.8 billion in 2024.
  • Business Quant data shows Accumulated Expenses for TMO at $1.8 billion in Q3 2024, $1.5 billion in Q2 2024, and $1.3 billion in Q1 2024.